Baillie Gifford & Co’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-463,945
| Closed | -$17.8M | – | 303 |
|
|
2023
Q2 | $17.8M | Sell |
463,945
-22,650
| -5% | -$582K | 0.02% | 186 |
|
|
2023
Q1 | $11.3M | Sell |
486,595
-3,113
| -0.6% | -$74.2K | 0.01% | 215 |
|
|
2022
Q4 | $12.8M | Buy |
489,708
+25,394
| +5% | +$563K | 0.01% | 206 |
|
|
2022
Q3 | $9.13M | Sell |
464,314
-40,511
| -8% | -$813K | 0.01% | 219 |
|
|
2022
Q2 | $8.83M | Sell |
504,825
-306,054
| -38% | -$4.8M | 0.01% | 218 |
|
|
2022
Q1 | $13.3M | Sell |
810,879
-32,933
| -4% | -$448K | 0.01% | 223 |
|
|
2021
Q4 | $13.8M | Buy |
843,812
+6,236
| +0.7% | +$88.8K | 0.01% | 235 |
|
|
2021
Q3 | $10.7M | Sell |
837,576
-1,804
| -0.2% | -$23.7K | 0.01% | 245 |
|
|
2021
Q2 | $11.9M | Sell |
839,380
-6,105
| -0.7% | -$97.6K | 0.01% | 242 |
|
|
2021
Q1 | $13.1M | Buy |
845,485
+801
| +0.1% | +$13.1K | 0.01% | 235 |
|
|
2020
Q4 | $13.4M | Sell |
844,684
-8,512
| -1% | -$128K | 0.01% | 214 |
|
|
2020
Q3 | $10.4M | Sell |
853,196
-3,348
| -0.4% | -$44.9K | 0.01% | 210 |
|
|
2020
Q2 | $9.89M | Buy |
856,544
+679
| +0.1% | +$9.36K | 0.01% | 196 |
|
|
2020
Q1 | $11.7M | Buy |
855,865
+9,414
| +1% | +$111K | 0.01% | 164 |
|
|
2019
Q4 | $5M | Buy |
846,451
+21,160
| +3% | +$115K | ﹤0.01% | 190 |
|
|
2019
Q3 | $4.37M | Buy |
825,291
+11,146
| +1% | +$74K | 0.01% | 193 |
|
|
2019
Q2 | $6.27M | Buy |
814,145
+47,860
| +6% | +$729K | 0.01% | 197 |
|
|
2019
Q1 | $15.2M | Buy |
766,285
+34,050
| +5% | +$594K | 0.02% | 174 |
|
|
2018
Q4 | $9.66M | Buy |
732,235
+116,870
| +19% | +$2.33M | 0.01% | 184 |
|
|
2018
Q3 | $22.6M | Buy |
615,365
+53,263
| +9% | +$1.71M | 0.02% | 151 |
|
|
2018
Q2 | $19.7M | Buy |
562,102
+230,755
| +70% | +$8.85M | 0.02% | 145 |
|
|
2018
Q1 | $15.4M | Buy |
331,347
+122,824
| +59% | +$4.5M | 0.02% | 155 |
|
|
2017
Q4 | $7.82M | Buy |
208,523
+97,905
| +89% | +$4.27M | 0.01% | 178 |
|
|
2017
Q3 | $5.89M | Buy |
110,618
+26,078
| +31% | +$1.55M | 0.01% | 180 |
|
|
2017
Q2 | $4.82M | Buy |
84,540
+26,540
| +46% | +$1.33M | 0.01% | 185 |
|
|
2017
Q1 | $3.12M | Hold |
58,000
| – | – | ﹤0.01% | 181 |
|
|
2016
Q4 | $3.31M | Hold |
58,000
| – | – | 0.01% | 185 |
|
|
2016
Q3 | $3.6M | Hold |
58,000
| – | – | 0.01% | 184 |
|
|
2016
Q2 | $3.28M | Buy |
58,000
+12,000
| +26% | +$729K | 0.01% | 181 |
|
|
2016
Q1 | $2.95M | Buy |
+46,000
| New | +$3.72M | 0.01% | 186 |
|
Baillie Gifford & Co's KDNY Position: Q3 2023 in Review
Baillie Gifford & Co sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 463,945 shares — an estimated $17.8M sold.
Baillie Gifford & Co first reported a position in KDNY in Q1 2016 and held it in 30 quarters. The position peaked at $22.6M in Q3 2018. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Baillie Gifford & Co reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Baillie Gifford & Co sold 463,945 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $17.8M.
- Baillie Gifford & Co first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2016 and held it in 30 quarters.
- Baillie Gifford & Co's Chinook Therapeutics, Inc. Common Stock position peaked at $22.6M in Q3 2018.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Baillie Gifford & Co's 13F filing for Q3 2023, filed 13 Nov 2023.